Wolverine Trading’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $7.25M | Buy |
16,200
+700
| +5% | +$285K | 0.01% | 1144 |
|
|
2025
Q2 | $5M | Buy |
15,500
+2,800
| +22% | +$775K | 0.01% | 1058 |
|
|
2025
Q1 | $3.41M | Buy |
12,700
+300
| +2% | +$77.1K | ﹤0.01% | 1241 |
|
|
2024
Q4 | $2.93M | Sell |
12,400
-13,900
| -53% | -$3.66M | ﹤0.01% | 1639 |
|
|
2024
Q3 | $7.23M | Sell |
26,300
-11,800
| -31% | -$3.07M | 0.01% | 852 |
|
|
2024
Q2 | $9.26M | Buy |
38,100
+14,200
| +59% | +$2.24M | 0.01% | 668 |
|
|
2024
Q1 | $3.57M | Buy |
23,900
+8,800
| +58% | +$1.47M | ﹤0.01% | 1216 |
|
|
2023
Q4 | $2.89M | Buy |
15,100
+4,100
| +37% | +$698K | ﹤0.01% | 1432 |
|
|
2023
Q3 | $1.95M | Buy |
11,000
+3,600
| +49% | +$687K | ﹤0.01% | 1611 |
|
|
2023
Q2 | $1.41M | Sell |
7,400
-2,900
| -28% | -$575K | ﹤0.01% | 1742 |
|
|
2023
Q1 | $2.01M | Buy |
10,300
+4,800
| +87% | +$1.01M | ﹤0.01% | 1367 |
|
|
2022
Q4 | $1.31M | Sell |
5,500
-700
| -11% | -$149K | ﹤0.01% | 1656 |
|
|
2022
Q3 | $1.3M | Sell |
6,200
-5,500
| -47% | -$1.05M | ﹤0.01% | 1736 |
|
|
2022
Q2 | $1.7M | Buy |
11,700
+3,300
| +39% | +$468K | ﹤0.01% | 1505 |
|
|
2022
Q1 | $1.39M | Sell |
8,400
-4,400
| -34% | -$670K | ﹤0.01% | 2111 |
|
|
2021
Q4 | $2.19M | Buy |
12,800
+6,500
| +103% | +$1.21M | ﹤0.01% | 1802 |
|
|
2021
Q3 | $1.12M | Sell |
6,300
-20,200
| -76% | -$3.79M | ﹤0.01% | 2848 |
|
|
2021
Q2 | $4.4M | Buy |
26,500
+17,800
| +205% | +$2.61M | 0.01% | 1261 |
|
|
2021
Q1 | $1.18M | Sell |
8,700
-3,400
| -28% | -$512K | ﹤0.01% | 2537 |
|
|
2020
Q4 | $1.59M | Sell |
12,100
-5,900
| -33% | -$788K | ﹤0.01% | 1922 |
|
|
2020
Q3 | $2.61M | Sell |
18,000
-2,400
| -12% | -$341K | 0.01% | 1273 |
|
|
2020
Q2 | $3.02M | Sell |
20,400
-2,300
| -10% | -$310K | 0.01% | 1117 |
|
|
2020
Q1 | $2.47M | Sell |
22,700
-10,200
| -31% | -$1.18M | 0.01% | 1185 |
|
|
2019
Q4 | $3.77M | Buy |
32,900
+2,000
| +6% | +$199K | 0.01% | 1324 |
|
|
2019
Q3 | $2.51M | Sell |
30,900
-1,900
| -6% | -$150K | 0.01% | 1281 |
|
|
2019
Q2 | $2.38M | Sell |
32,800
-3,500
| -10% | -$269K | 0.01% | 1378 |
|
|
2019
Q1 | $3.39M | Sell |
36,300
-12,900
| -26% | -$1.08M | 0.01% | 1130 |
|
|
2018
Q4 | $3.46M | Sell |
49,200
-21,000
| -30% | -$1.62M | 0.01% | 1043 |
|
|
2018
Q3 | $6.14M | Buy |
70,200
+25,100
| +56% | +$2.52M | 0.01% | 843 |
|
|
2018
Q2 | $5.37M | Hold |
45,100
| – | – | 0.01% | 815 |
|
|
2018
Q1 | $5.37M | Sell |
45,100
-11,100
| -20% | -$1.43M | 0.01% | 815 |
|
|
2017
Q4 | $7.14M | Buy |
+56,200
| New | +$7.06M | 0.03% | 657 |
|
|
2017
Q1 | – | Sell |
-87,800
| Closed | -$3.29M | – | 4168 |
|
|
2016
Q4 | $3.29M | Buy |
+87,800
| New | +$3.68M | 0.02% | 989 |
|
Other funds holding ALNY
Wolverine Trading's ALNY Position: Q3 2025 in Review
Wolverine Trading increased its Alnylam Pharmaceuticals (ALNY) stake by 458% in Q3 2025, buying an estimated $2.09M and bringing the position to 6,262 shares worth $2.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1879.
Wolverine Trading first reported a position in ALNY in Q4 2016 and has held it in 19 quarters since. 821 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.
- Wolverine Trading held 6,262 shares of Alnylam Pharmaceuticals worth $2.8M as of Q3 2025.
- Wolverine Trading bought 5,140 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $2.09M.
- Alnylam Pharmaceuticals made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #1879 holding.
- Wolverine Trading first reported a position in Alnylam Pharmaceuticals in Q4 2016 and has held it in 19 quarters since.
- 821 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.
Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.